VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TLX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksTLXInstitutional Holders

TLX logoTelix Pharmaceuticals Limited (TLX) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership increased this quarter (+0.13 pp), though top 10 holders maintain a highly concentrated 73.6% of institutional value.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
0.9%$34M total value · ▲ +0.13 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
63 / 100Bullish
Institutions & Flow61 holders+21 net flow (+22 / -1)

AI Insights & Key Takeaways

  • Positive Institutional Flow (+21)
  • Jane Street Group, Llc maintains a significant position
  • Top 10 holders control 73.6% of institutional value
  • No Insider Signal

Top Institutional Holders of TLX

Ranked by reported Q2 2026 13F market value

Top 10 Holders
73.6%
Top 25 Holders
97.2%

Share of total reported institutional value in TLX held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1FMR LLC561K$6.5M-0.6%0.166%0.00%
2LAZARD ASSET MANAGEMENT LLC284K$3.3M-2.0%0.084%0.00%
3PORTLAND INVESTMENT COUNSEL INC.266K$3.1M0.0%0.079%0.86%

Quarterly Institutional Activity

Filings activity in TLX during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers22Added To33Trimmed4Exited1
  • MARSHALL WACE, LLP$2.2M
  • BLAIR WILLIAM & CO/IL$1.4M
  • Quadrature Capital Ltd

TLX Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 202661+56%0.89%+0.13 pp$34M+41%
Q1 202639+0.0%0.76%+0.43 pp$24M+189%
Q4 202539+44%0.33%+0.09 pp$8M+9.0%
Q3 202527+23%0.24%+0.11 pp$8M+6.6%
Q2 202522+214%0.13%+0.12 pp$7M+812%
Q1 20257+250%

How TLX Compares to Peers

Institutional ownership and quarterly buying activity across the largest Oncology Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
DMRADamora Therapeutics, Inc.$1.46B200.0%99+33
FTHFaeth Therapeutics, Inc.$568M54.5%45+16
LONALeonaBio, Inc.$17M184.4%45+4
KYNBKyntra Bio, Inc.$15M26.9%29-4
CNSYCerenome, Inc.$5M4.8%24-5

TLX — Frequently Asked Questions

Quick answers to the most common questions about buying TLX stock.

What percentage of TLX is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of Telix Pharmaceuticals Limited stands at 0.9%, held across 61 reporting institutions.

Who is the largest institutional holder of TLX?

FMR LLC is the largest reported institutional holder of TLX, with approximately 561,206 shares worth $0.01B as of Q2 2026.

Is TLX a hedge fund favorite?

Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of TLX, including JANE STREET GROUP, LLC.

What is TLX's Smart Money Score?

Our composite Smart Money Score for TLX is 63 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought TLX this quarter?

22 institutions opened new positions in TLX during Q2 2026, while 1 fully exited. 33 added to existing positions and 4 trimmed.

4Private Advisor Group, LLC197K$2.3M+13.1%0.058%0.01%
5MARSHALL WACE, LLP189K$2.2M—0.056%0.00%
6MORGAN STANLEY166K$1.9M+42.5%0.049%0.00%
7Integrated Wealth Concepts LLC164K$1.9M0.0%0.049%0.01%
8UBS Group AG135K$1.6M+317.0%0.040%0.00%
9BLAIR WILLIAM & CO/IL123K$1.4M—0.036%0.00%
10Raiffeisen Bank International AG115K$1.3M-11.5%0.034%0.02%
11Quadrature Capital Ltd102K$1.2M—0.030%0.01%
12JPMORGAN CHASE & CO78K$876K+35.2%0.023%0.00%
13XY Capital Ltd71K$822K+468.0%0.021%0.79%
14XTX Topco Ltd69K$793K+164.5%0.020%0.01%
15Vanguard Personalized Indexing Management, LLC59K$680K+77.4%0.017%0.01%
16NLB Skladi, upravljanje premozenja, d.o.o.58K$669K—0.017%0.03%
17Mariner, LLC37K$428K-14.6%0.011%0.00%
18Capricorn Fund Managers Ltd36K$416K—0.011%0.03%
19GTS SECURITIES LLC36K$410K—0.011%0.01%
20JANE STREET GROUP, LLC33K$385K—0.010%0.00%
21IHT Wealth Management, LLC32K$372K+29.0%0.009%0.01%
22SummitTX Capital, L.P.32K$365K—0.009%0.01%
23Portolan Capital Management, LLC25K$293K-95.3%0.007%0.01%
24BNP PARIBAS FINANCIAL MARKETS21K$237K+71.0%0.006%0.00%
25HSBC HOLDINGS PLC16K$190K—0.005%0.00%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in TLX — a direct measure of their conviction.

$1.2M
  • NLB Skladi, upravljanje premozenja, d.o.o.$669K
  • Capricorn Fund Managers Ltd$416K
  • GTS SECURITIES LLC$410K
  • JANE STREET GROUP, LLC$385K
  • SummitTX Capital, L.P.$365K
  • HSBC HOLDINGS PLC$190K
  • Orion Porfolio Solutions, LLC$180K
  • NATIXIS$127K
  • TWO SIGMA INVESTMENTS, LP$118K
  • 0.01%
    +0.01 pp
    $1M
    +1290%
    Q4 20242+100%0.00%—$0M—
    Q2 20241———$0M—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    How is institutional ownership of TLX changing?

    TLX institutional ownership rose by 0.13 percentage points quarter-over-quarter, with a net change of +22 holders.

    How concentrated is TLX ownership among the top holders?

    The top 10 institutions account for 73.6% of all reported 13F value in TLX, and the top 25 account for 97.2%.

    How does TLX compare to Oncology Biotech on institutional ownership?

    Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.

    Where does this TLX institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    TLXTelix Pharmaceuticals Limited
    $8.96$3.0B
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership